Inventor

SUGIYAMA HARUO

JP75 patents

⚠️ This page may combine multiple inventors who share the name “SUGIYAMA HARUO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

SUGIYAMA HARUO

INT INST CANCER IMMUNOLOGY INC

Tumor antigen based on products of the tumor suppressor gene WT1

Tumor antigen based on products of the tumor suppressor gene WT1

Cancer antigen peptides derived from WT1

Cancer antigen peptide formulations

Tumor antigen based on products of the tumor suppressor gene WT1

Tumor antigen based on products of the tumor suppressor gene WT1

HLA-A24-restricted cancer antigen peptides

WT1 substitution peptides

Cancer vaccine composition

HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the same

Cancer vaccine composition

Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same

Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same

Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same

Cancer vaccine composition

Cancer antigen helper peptide

Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them

Receptor gene for peptide cancer antigen-specific T cell

Immunotherapy for angiogenic disease

HLA-DR-binding antigen peptide derived from WT1

Combination therapy with WT1 peptide vaccine and temozolomide

Composition for preventing or treating benign tumor

Cancer antigen helper peptide

Method for activation of helper t cell and composition for use in the method

SUGIYAMA HARUO

Method of detecting solid cancer cells and tissue atypia and method of testing tissues for use in bone marrow transplantation and peripheral blood stem cell transplantation

Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same

Cancer vaccine composition

Cancer antigen peptides derived from WT1

WT1 modified peptide

Tumor antigen based on products of the tumor suppressor gene WT1

Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them

Receptor gene for peptide cancer antigen-specific T cell

Cancer antigen helper peptide

HLA-A* 3303-restricted WT1 peptide and pharmaceutical composition comprising the same

Method of inducing antigen-specific T cells

siRNA specific to WT1 17AA(−)isoform and use thereof

Method for examining WT1-related disease

Method for activation of helper T cell and composition for use in the method

Cancer antigen eEF2

Method for activating helper T cell

KISHIMOTO TADAMITSU

Growth inhibitor for leukemia cells comprising antisense oligonucleotide derivative to wilms tumor gene (wt1)

Growth inhibitor for leukemia cell comprising antisense oligonucleotide derivative to wilms tumor gene (WT1)

UNIV OSAKA

Antibody

Antibody

NITTO DENKO CORP

Vaccine composition

WT1 peptide cancer vaccine composition for transdermal administration

HARUO SUGIYAMA

Tumor antigen based on products of the tumor suppressor gene WT1

DAINIPPON SUMITOMO PHARMA CO

HLA-A24-restricted cancer antigen peptides

OKI YOSHITO

High strength aluminum alloy fin material for heat exchanger and method for production thereof

TOSHIBA KK

Lamp quality judgement apparatus and judgement method therefor